Identifying relevant HLA-F ligands
Identifying relevant HLA-F ligands
批准号:
10171782
负责人:
Roland K Strong
金额:
$15.95万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-01 至 2022-03-31
关键词:
Activated LymphocyteAllelesAmino AcidsAmyotrophic Lateral SclerosisAntigen Presentation PathwayAntigensAntiviral ResponseApplications GrantsBindingBiochemicalBiologicalCD8-Positive T-LymphocytesCancerousCell Surface ProteinsCell surfaceCellsCircular Dichroism SpectroscopyComplexCorrelative StudyCoupledCross PresentationCrystallizationDataDevelopmentDiseaseFutureGlioblastomaGlycoconjugatesGlycopeptidesGlycoproteinsGoalsHLA-A2 AntigenHistocompatibility Antigens Class IHumanImmuneImmune responseImmune systemImmunityInflammatory ResponseInsectaKIR3DS1Ligand BindingLigandsLipidsMHC Class I GenesMHC InteractionMediatingMethodsMicrobeModelingModificationNasopharynx CarcinomaNatural Killer CellsOligosaccharidesOutputPathogenesisPathway interactionsPatient-Focused OutcomesPeptidesPeptidoglycanPeripheral Nervous SystemPhysiologicalPlasmodium falciparumPlayPolysaccharidesPregnancyPreventionProtein FragmentProteinsRecombinantsResearchRoleSamplingSeminalSideSourceSpecificityStructureSurfaceSurface Plasmon ResonanceSystemT-LymphocyteTestingToxoplasma gondiiTryptophanVaccinesValidationX-Ray Crystallographybaseconformerelectron densityextracellularimprovedinsightinterestmolecular recognitionnovelpathogenprogramsprotein expressionscreeningsmall moleculesuccesstumoruptake
中文摘要
项目摘要/总结
英文摘要
Project Abstract/Summary
· Our underlying hypothesis is that, unlike human classical and other non-classical MHC class I proteins, HLA-
F ligand recognition is focused on glycans, either as components of oligosaccharides, proteo/peptidoglycans, or
glycoproteins/glycopeptides – representing a paradigm shift in current understanding. This hypothesis is based
on a rigorous reevaluation of recent, otherwise seminal crystallographic and mass-spec results (1).
· Echoing FOA PA-19-066, our long-term overall goal is “to characterize antigen processing and presentation
[…] of novel peptidic and non-peptidic ligands presented by [HLA-F], and to determine the contribution of these
unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-
associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated dis-
eases.” Our first steps towards accomplishing this goal in this R21 will be to: (a) identify physiologically-
relevant ligand/s for HLA-F using rigorous biochemical approaches, focusing on glycopeptides and glycoconju-
gates; and (b) determine conditions for growing diffraction-quality co-crystals to support future crystallographic
structure determinations. These results will comprise the necessary preliminary results to support follow-on grant
applications to structurally, biologically, and functionally validate candidate HLA-F glycoligands.
· We will achieve these goals, and rigorously test our hypothesis, through the following Specific Aim: we will
use our novel ARTEMIS mass-spec peptide discovery platform, glycan arrays, and fragment screening ap-
proaches, to fully parse HLA-F ligand specificity for glycosylated ligands. Candidate ligands will be used to screen
crystallization conditions to support follow-on crystallographic studies to eventually structurally characterize
recognition mechanisms to fully parse specificity. Rigor will ultimately be achieved through careful biochemical
and structural validation, and the likelihood of success will be maximized by incorporating multiple, parallel ap-
proaches and experimental methods into the proposed scope to overcome potential confounders and pitfalls.
· Significance (from PA-19-066): “The classic understanding of antigen processing and presentation begins
with a protein fragment (peptide) associating with MHC molecules. […] These long-accepted paradigms regard-
ing antigen processing and presentation and T cell recognition are incomplete. Approximately 10% of antigenic
peptides can be derived from unconventional sources […]. Additionally, the antigen components that trigger non-
classical MHC I restricted CD8 T cells and unconventional or innate T cells include lipids and small-molecule
metabolites but are not well characterized. […] The objective of this research program is to promote the discovery
of unique antigenic ligands (peptidic and non-peptidic) and understand the immune responses to these ligands:
peptidic and non-peptidic ligands presented by non-classical MHC molecules: [HLA-F].”
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
-
批准号:10674405
-
项目类别:
-
资助金额:$80.42万
-
财政年份:2023
-
负责人:Roland K Strong
-
依托单位:
Identifying relevant HLA-F ligands
-
批准号:10593460
-
项目类别:
-
资助金额:$10.45万
-
财政年份:2020
-
负责人:Roland K Strong
-
依托单位:
TCR-like antibodies for HPV-induced cancer basic research and theranostics
-
批准号:9319153
-
项目类别:
-
资助金额:$43.5万
-
财政年份:2016
-
负责人:Roland K Strong
-
依托单位:
TCR-like antibodies for HPV-induced cancer basic research and theranostics
-
批准号:9178025
-
项目类别:
-
资助金额:$44.23万
-
财政年份:2016
-
负责人:Roland K Strong
-
依托单位:
Structure/function studies of immunogen recognition by anti-HIV antibody b12
-
批准号:8463117
-
项目类别:
-
资助金额:$57.18万
-
财政年份:2013
-
负责人:Roland K Strong
-
依托单位:
B7-based, CD28 or CTLA-4-specific agonists and antagonists for tolerance inductio
-
批准号:8302052
-
项目类别:
-
资助金额:$21.31万
-
财政年份:2012
-
负责人:Roland K Strong
-
依托单位:
B7-based, CD28 or CTLA-4-specific agonists and antagonists for tolerance inductio
-
批准号:8432007
-
项目类别:
-
资助金额:$25.64万
-
财政年份:2012
-
负责人:Roland K Strong
-
依托单位:
Structure/function studies of immunogen recognition by anti-HIV antibody b12
-
批准号:8117982
-
项目类别:
-
资助金额:$53.84万
-
财政年份:2011
-
负责人:Roland K Strong
-
依托单位:
Microbial siderophore-specific innate immune responses
-
批准号:7022967
-
项目类别:
-
资助金额:$28.7万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
Microbial siderophore-specific innate immune responses
-
批准号:6872755
-
项目类别:
-
资助金额:$29.41万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
Microbial siderophore-specific innate immune responses
-
批准号:7189847
-
项目类别:
-
资助金额:$27.85万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
RIGAKU/MSC HIGH-THROUGHPUT HOMELAB X-RAY CRYSTALLOGRAPHY SYSTEM: IMMUNOLOGY
-
批准号:7166688
-
项目类别:
-
资助金额:$11.48万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
RIGAKU/MSC HIGH-THROUGHPUT HOMELAB X-RAY CRYSTALLOGRAPHY SYSTEM: HEMATOLOGY
-
批准号:7166689
-
项目类别:
-
资助金额:$1.38万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
Rigaku/MSC High-Throughput HomeLab x-ray crystallography system
-
批准号:7042646
-
项目类别:
-
资助金额:$45.9万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
Microbial siderophore-specific innate immune responses
-
批准号:7373651
-
项目类别:
-
资助金额:$27.3万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
RIGAKU/MSC HIGH-THROUGHPUT HOMELAB X-RAY CRYSTALLOGRAPHY SYSTEM: BIOCHEMISTRY
-
批准号:7166687
-
项目类别:
-
资助金额:$33.05万
-
财政年份:2005
-
负责人:Roland K Strong
-
依托单位:
Structural Studies of the MIC/NKG 2D Interaction
-
批准号:6369823
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2001
-
负责人:Roland K Strong
-
依托单位:
Structure/function studies of CTLD NK immunoreceptors
-
批准号:7576177
-
项目类别:
-
资助金额:$35.91万
-
财政年份:2001
-
负责人:Roland K Strong
-
依托单位:
Structural Studies of the MIC/NKG 2D Interaction
-
批准号:6511398
-
项目类别:
-
资助金额:$29.36万
-
财政年份:2001
-
负责人:Roland K Strong
-
依托单位:
Structure/function studies of CTLD NK immunoreceptors
-
批准号:8145446
-
项目类别:
-
资助金额:$10.29万
-
财政年份:2001
-
负责人:Roland K Strong
-
依托单位:
海外基金